CIK 0001776111 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MBX Biosciences, Inc.
Sign in to watch- Ticker
- MBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 3179893100
- Business address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,361
- in 2 filings
Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | Yang Rick 10% owner | Conversion | +1,023,103 | 1,023,103 | ||
| 2024-09-16 | Yang Rick 10% owner | Conversion | +2,091,383 | 3,114,486 | ||
| 2024-09-16 | Yang Rick 10% owner | Purchase | +500,000 | $16.00 | $8.0M | 3,614,486 |
| 2024-09-16 | Yang Rick 10% owner | Conversion · Series A Convertible Preferred Stock | −12,299,854 | 0 | ||
| 2024-09-16 | Yang Rick 10% owner | Conversion · Series B Convertible Preferred Stock | −25,142,840 | 0 | ||
| 2024-09-16 | SANDELL SCOTT D 10% owner | Conversion | +1,023,103 | 1,023,103 | ||
| 2024-09-16 | SANDELL SCOTT D 10% owner | Conversion | +2,091,383 | 3,114,486 | ||
| 2024-09-16 | SANDELL SCOTT D 10% owner | Purchase | +500,000 | $16.00 | $8.0M | 3,614,486 |
| 2024-09-16 | SANDELL SCOTT D 10% owner | Conversion · Series A Convertible Preferred Stock | −12,299,854 | 0 | ||
| 2024-09-16 | SANDELL SCOTT D 10% owner | Conversion · Series B Convertible Preferred Stock | −25,142,840 | 0 | ||
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Conversion | +2,658,428 | 2,658,428 | ||
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Conversion | +403,787 | 403,787 | ||
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Purchase | +500,000 | $16.00 | $8.0M | 3,158,428 |
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Purchase | +250,000 | $16.00 | $4.0M | 653,787 |
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Conversion · Series A Convertible Preferred Stock | −12,372,634 | 0 | ||
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Conversion · Series B Convertible Preferred Stock | −19,587,284 | 0 | ||
| 2024-09-16 | ORBIMED ADVISORS LLC Director | Conversion · Series C Convertible Preferred Stock | −4,854,368 | 0 | ||
| 2024-09-16 | New Enterprise Associates 17, L.P. 10% owner | Conversion | +1,023,103 | 1,023,103 | ||
| 2024-09-16 | New Enterprise Associates 17, L.P. 10% owner | Conversion | +2,091,383 | 3,114,486 | ||
| 2024-09-16 | New Enterprise Associates 17, L.P. 10% owner | Purchase | +500,000 | $16.00 | $8.0M | 3,614,486 |
Page 6 of 9 · 164 trades